Armata's Blood-Infection Drug Shows Positive Results in Mid-Stage Trial

Dow Jones

Oct 23

By Connor Hart

Armata Pharmaceuticals said its experimental treatment for a serious bloodstream infection showed positive results in a recent mid-stage trial.

The Los Angeles-based biotech company said Wednesday that its drug, AP-SA02, outperformed standard antibiotics in patients with complicated Staphylococcus aureus bacteremia, a severe and often life-threatening blood infection.

In a Phase 2a study, patients receiving AP-SA02 alongside conventional antibiotics showed higher improvement rates than those given antibiotics alone. No patients in the AP-SA02 group experienced relapse or treatment failure during follow-up, compared with about 25% in the placebo group, the company said.

Chief Executive Deborah Birx said Armata plans to advance AP-SA02 into a Phase 3 trial next year, pending Food and Drug Administration review.

Shares jumped 95% to $6.78 before trading was paused for volatility.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

October 22, 2025 12:06 ET (16:06 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2577391241"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577391241\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577391241?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-23 00:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577391241","market":"sh","top_or_hot":-1,"title":"Armata's Blood-Infection Drug Shows Positive Results in Mid-Stage Trial","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Armata Pharmaceuticals said its experimental treatment for a serious bloodstream infection showed positive results in a recent mid-stage trial. \n</p>\n<p>\n  The Los Angeles-based biotech company said Wednesday that its drug, AP-SA02, outperformed standard antibiotics in patients with complicated Staphylococcus aureus bacteremia, a severe and often life-threatening blood infection. \n</p>\n<p>\n  In a Phase 2a study, patients receiving AP-SA02 alongside conventional antibiotics showed higher improvement rates than those given antibiotics alone. No patients in the AP-SA02 group experienced relapse or treatment failure during follow-up, compared with about 25% in the placebo group, the company said. \n</p>\n<p>\n  Chief Executive Deborah Birx said Armata plans to advance AP-SA02 into a Phase 3 trial next year, pending Food and Drug Administration review. \n</p>\n<p>\n  Shares jumped 95% to $6.78 before trading was paused for volatility. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 22, 2025 12:06 ET (16:06 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Armata's Blood-Infection Drug Shows Positive Results in Mid-Stage Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArmata's Blood-Infection Drug Shows Positive Results in Mid-Stage Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-23 00:06</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Armata Pharmaceuticals said its experimental treatment for a serious bloodstream infection showed positive results in a recent mid-stage trial. \n</p>\n<p>\n  The Los Angeles-based biotech company said Wednesday that its drug, AP-SA02, outperformed standard antibiotics in patients with complicated Staphylococcus aureus bacteremia, a severe and often life-threatening blood infection. \n</p>\n<p>\n  In a Phase 2a study, patients receiving AP-SA02 alongside conventional antibiotics showed higher improvement rates than those given antibiotics alone. No patients in the AP-SA02 group experienced relapse or treatment failure during follow-up, compared with about 25% in the placebo group, the company said. \n</p>\n<p>\n  Chief Executive Deborah Birx said Armata plans to advance AP-SA02 into a Phase 3 trial next year, pending Food and Drug Administration review. \n</p>\n<p>\n  Shares jumped 95% to $6.78 before trading was paused for volatility. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 22, 2025 12:06 ET (16:06 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2577391241","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577391241","pubTimestamp":1761149160,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Armata Pharmaceuticals said its experimental treatment for a serious bloodstream infection showed positive results in a recent mid-stage trial.The Los Angeles-based biotech company said Wednesday that its drug, AP-SA02, outperformed standard antibiotics in patients with complicated Staphylococcus aureus bacteremia, a severe and often life-threatening blood infection.In a Phase 2a study, patients receiving AP-SA02 alongside conventional antibiotics showed higher improvement rates than those given antibiotics alone. No patients in the AP-SA02 group experienced relapse or treatment failure during follow-up, compared with about 25% in the placebo group, the company said.Chief Executive Deborah Birx said Armata plans to advance AP-SA02 into a Phase 3 trial next year, pending Food and Drug Administration review.Shares jumped 95% to $6.78 before trading was paused for volatility.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SSI":"Stage Stores Inc","ARMP":"Armata Pharmaceuticals, Inc."},"translate_title":"Armata的血液感染药物在中期试验中显示出积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARMP":0.9,"SSI":1.5},"content_text":"By Connor Hart \n\n\n \n\n\n  Armata Pharmaceuticals said its experimental treatment for a serious bloodstream infection showed positive results in a recent mid-stage trial. \n\n\n  The Los Angeles-based biotech company said Wednesday that its drug, AP-SA02, outperformed standard antibiotics in patients with complicated Staphylococcus aureus bacteremia, a severe and often life-threatening blood infection. \n\n\n  In a Phase 2a study, patients receiving AP-SA02 alongside conventional antibiotics showed higher improvement rates than those given antibiotics alone. No patients in the AP-SA02 group experienced relapse or treatment failure during follow-up, compared with about 25% in the placebo group, the company said. \n\n\n  Chief Executive Deborah Birx said Armata plans to advance AP-SA02 into a Phase 3 trial next year, pending Food and Drug Administration review. \n\n\n  Shares jumped 95% to $6.78 before trading was paused for volatility. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 22, 2025 12:06 ET (16:06 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}